Description
Xgen Tranexamic Acid (TXA) for Injection 100 mg Injection Single-Dose Vial 10 mL x 10/Box
Xgen Tranexamic Acid for Injection 100 mg in a Single-Dose Vial. An injectable form of tranexamic acid is available which is used to improve the surgical outcome in patients with heavy blood loss. Tranexamic acid is a weak fibrinolytic agent that competitively inhibits plasminogen activation, and thereby diminishes the degradation of fibrinogen, plasminogen, and fibrin.
According to a study published in the Journal of the American Medical Association, tranexamic acid (TXA) may be a life-saving drug for women with severe bleeding after childbirth. The study found that TXA cut the death rate from post-birth hemorrhage in half.
TXA is a drug that helps to reduce bleeding by slowing down the breakdown of blood clots. It is often used to prevent blood loss in people with kidney disease, cancer, or after surgery.
The study included more than 20,000 women who had a cesarean section or were in labor and experienced severe bleeding. Half of the women were given TXA and the other half were not.
The researchers found that the death rate from post-birth hemorrhage was lower in the women who received TXA (0.9 percent) than in the women who did not receive TXA (1.8 percent).
TXA was also found to be effective in preventing blood transfusions and the need for surgery to control the bleeding.
TXA is an inexpensive drug and is available in generic form. It does not have any major side effects.
The authors of the study say that TXA should be given to all women who are at risk for severe bleeding after childbirth.
